CSF2 and neoplasm: Phase I and II T-VEC trials revealed replication of the oncolytic virus within tumor cells, the expression of GM-CSF, and an overall response rate of 26% in the intralesional T-VEC group compared to 6% in the group given subcutaneous GM-CSF [63–65].